About us
An independent guide to Retatrutide for Australians
retatrutide.net.au exists to give Australians clear, accurate, up-to-date information on Retatrutide as it moves through clinical trials toward possible TGA approval.
Who we are
Independent, and not affiliated with any manufacturer
This site is run by an independent Australian editorial team. We are not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or any pharmaceutical manufacturer. We created retatrutide.net.au because interest in Retatrutide is growing quickly in Australia while reliable, plainly-written local information is scarce — and we wanted to fill that gap responsibly.
Editorial standards
How we research and write
We work from primary sources
Our figures and claims are drawn from primary and peer-reviewed sources — Eli Lilly's official trial announcements, publications such as The Lancet and the New England Journal of Medicine, the Therapeutic Goods Administration (TGA), and the Australian Institute of Health and Welfare (AIHW). We link to those sources so you can check them yourself.
We separate results from expectations
We're careful to distinguish what clinical trials have actually shown from what is still being studied or projected. Where a timeline or outcome is uncertain — including when or whether Retatrutide will be approved in Australia — we say so plainly.
We update as the science moves
Retatrutide is progressing through an active Phase 3 program with new readouts through 2026 and beyond. We publish ongoing coverage and revise existing pages as new data and regulatory news emerge.
We don't sell or supply it
We are an information resource, not a pharmacy or supplier. Retatrutide is investigational and not TGA-approved; it cannot be legally purchased. Nothing on this site is medical advice — always speak with a qualified Australian health professional about your own circumstances.
Contact & corrections
Spotted something to fix?
We take accuracy seriously. If you believe something on this site is out of date or incorrect, or you're a clinician or researcher who would like to contribute, email info@retatrutide.net.au and we'll review it.
Disclaimer: This website is for general information only and is not medical advice. Retatrutide is an investigational medicine and has not been approved by the TGA. Always consult a qualified Australian health professional before making decisions about your health or treatment.
Stay informed
Be first to know when Retatrutide reaches Australia.
Retatrutide is not yet available to the public. But when it is, you will want to be first to know. Sign up to receive:
- The latest clinical trial results and news from Eli Lilly
- Updates on TGA regulatory progress in Australia
- How and where to access Retatrutide when it becomes available
- A direct link to a trusted source to learn more
